Business Wire
BusinessEli Lilly shares have held up better than the Dow over the past year, according to market-watchersThe Apex TimesBusinessEli Lilly credited with “major FDA win” for weight-loss drug in latest market reportThe Apex TimesBusinessCostco shopping picks and the market’s rate-hike watch: A Yahoo Finance “Go in the Know” roundupThe Apex TimesBusinessMarkets Tread Water as Jackson Hole Remarks Close; Microsoft Leads Tech Upward MoveThe Apex TimesBusinessBerkshire Hathaway closes $6.8 billion Taylor Morrison deal, deepening its homebuilding footprintThe Apex TimesBusinessWalmart to add Apple Pay and Google Pay to US checkout by end of 2026, narrowing gap in contactless paymentsThe Apex TimesBusinessPalantir’s “Rule of 40” jumps to 155%, pointing to faster growth and wider adjusted marginsThe Apex TimesBusinessNetflix’s Path Toward $100: Buybacks and a Bigger Ads Push Are Drawing Fresh AttentionThe Apex TimesBusinessJPMorgan taps David Fishman from Bank of America to lead North America technology M&A, Reuters reportsThe Apex TimesBusinessEli Lilly shares sit near $1,175, but a Yahoo Finance note points to relative performance as the case for the stockThe Apex TimesBusinessModerna and Merck report late-stage win for personalized melanoma vaccine with KeytrudaThe Apex TimesBusinessMicrosoft shares flash a fresh buy announcement after a breakout, reinforcing Wall Street’s AI focusThe Apex TimesBusinessEli Lilly shares have held up better than the Dow over the past year, according to market-watchersThe Apex TimesBusinessEli Lilly credited with “major FDA win” for weight-loss drug in latest market reportThe Apex TimesBusinessCostco shopping picks and the market’s rate-hike watch: A Yahoo Finance “Go in the Know” roundupThe Apex TimesBusinessMarkets Tread Water as Jackson Hole Remarks Close; Microsoft Leads Tech Upward MoveThe Apex TimesBusinessBerkshire Hathaway closes $6.8 billion Taylor Morrison deal, deepening its homebuilding footprintThe Apex TimesBusinessWalmart to add Apple Pay and Google Pay to US checkout by end of 2026, narrowing gap in contactless paymentsThe Apex TimesBusinessPalantir’s “Rule of 40” jumps to 155%, pointing to faster growth and wider adjusted marginsThe Apex TimesBusinessNetflix’s Path Toward $100: Buybacks and a Bigger Ads Push Are Drawing Fresh AttentionThe Apex TimesBusinessJPMorgan taps David Fishman from Bank of America to lead North America technology M&A, Reuters reportsThe Apex TimesBusinessEli Lilly shares sit near $1,175, but a Yahoo Finance note points to relative performance as the case for the stockThe Apex TimesBusinessModerna and Merck report late-stage win for personalized melanoma vaccine with KeytrudaThe Apex TimesBusinessMicrosoft shares flash a fresh buy announcement after a breakout, reinforcing Wall Street’s AI focusThe Apex TimesBusinessEli Lilly shares have held up better than the Dow over the past year, according to market-watchersThe Apex TimesBusinessEli Lilly credited with “major FDA win” for weight-loss drug in latest market reportThe Apex TimesBusinessCostco shopping picks and the market’s rate-hike watch: A Yahoo Finance “Go in the Know” roundupThe Apex TimesBusinessMarkets Tread Water as Jackson Hole Remarks Close; Microsoft Leads Tech Upward MoveThe Apex TimesBusinessBerkshire Hathaway closes $6.8 billion Taylor Morrison deal, deepening its homebuilding footprintThe Apex TimesBusinessWalmart to add Apple Pay and Google Pay to US checkout by end of 2026, narrowing gap in contactless paymentsThe Apex TimesBusinessPalantir’s “Rule of 40” jumps to 155%, pointing to faster growth and wider adjusted marginsThe Apex TimesBusinessNetflix’s Path Toward $100: Buybacks and a Bigger Ads Push Are Drawing Fresh AttentionThe Apex TimesBusinessJPMorgan taps David Fishman from Bank of America to lead North America technology M&A, Reuters reportsThe Apex TimesBusinessEli Lilly shares sit near $1,175, but a Yahoo Finance note points to relative performance as the case for the stockThe Apex TimesBusinessModerna and Merck report late-stage win for personalized melanoma vaccine with KeytrudaThe Apex TimesBusinessMicrosoft shares flash a fresh buy announcement after a breakout, reinforcing Wall Street’s AI focusThe Apex TimesBusinessEli Lilly shares have held up better than the Dow over the past year, according to market-watchersThe Apex TimesBusinessEli Lilly credited with “major FDA win” for weight-loss drug in latest market reportThe Apex TimesBusinessCostco shopping picks and the market’s rate-hike watch: A Yahoo Finance “Go in the Know” roundupThe Apex TimesBusinessMarkets Tread Water as Jackson Hole Remarks Close; Microsoft Leads Tech Upward MoveThe Apex TimesBusinessBerkshire Hathaway closes $6.8 billion Taylor Morrison deal, deepening its homebuilding footprintThe Apex TimesBusinessWalmart to add Apple Pay and Google Pay to US checkout by end of 2026, narrowing gap in contactless paymentsThe Apex TimesBusinessPalantir’s “Rule of 40” jumps to 155%, pointing to faster growth and wider adjusted marginsThe Apex TimesBusinessNetflix’s Path Toward $100: Buybacks and a Bigger Ads Push Are Drawing Fresh AttentionThe Apex TimesBusinessJPMorgan taps David Fishman from Bank of America to lead North America technology M&A, Reuters reportsThe Apex TimesBusinessEli Lilly shares sit near $1,175, but a Yahoo Finance note points to relative performance as the case for the stockThe Apex TimesBusinessModerna and Merck report late-stage win for personalized melanoma vaccine with KeytrudaThe Apex TimesBusinessMicrosoft shares flash a fresh buy announcement after a breakout, reinforcing Wall Street’s AI focusThe Apex Times
Back to front
Value Investor Says Palantir Looks Cheaper Than Expected, but He Still Won’t Buy Until a Specific Price
The Apex Times

THE APEX TIMES

Business/The Apex Times/Aug 28, 11:47 AM EDT

Value Investor Says Palantir Looks Cheaper Than Expected, but He Still Won’t Buy Until a Specific Price

A reported valuation “stress test” suggests Palantir may be priced below what one value-focused investor expected, yet the investor says he would wait for a defined lower level before stepping in.

2 min readEditor-approved Apex article

A value investor has drawn attention to Palantir by arguing the company’s stock looked cheaper than he expected after running it through the same type of downside-focused valuation work he applies to fast-growing companies, according to a report published by 247wallst on August 28, 2026.

The article frames Palantir as a case where the numbers passed some “stress test” assumptions better than anticipated, leading the investor to describe a valuation gap versus what he expected to find. It also portrays the investor as unwilling to act immediately, even if the conclusion is more favorable than expected, because he still wants to see the stock reach a specific price level.

Beyond the headline takeaway, the report emphasizes the investor’s frank admission that there are still elements he cannot fully explain about the business and the market’s willingness to price it for growth. That combination, the article suggests, is why the investor remains on the sidelines despite arriving at a “cheaper-than-expected” conclusion.

Palantir, which trades on the Nasdaq under the ticker PLTR, is widely followed in markets as a software company tied to large-scale data and analytics. In practice, investors often debate how to value companies whose revenue can be influenced by long sales cycles, customer adoption ramps, and the degree to which software platforms translate into durable margins. The 247wallst piece, by centering on valuation stress-testing, fits that broader style of debate.

Market participants tend to treat “stress test” valuations as a way to pressure-test assumptions about growth, margins, and discount rates. A favorable outcome from such work can bolster the argument that a stock is priced attractively relative to cash-flow expectations under challenging scenarios. In this case, the report implies that those assumptions produced a more optimistic view than the investor expected going in.

Still, the key practical point from the report is not that the investor is buying now, but that he is waiting for a particular price. The article’s framing therefore reads more like guidance on where risk may appear to be better compensated than a statement about near-term fundamentals.

What remains unclear from the available material is the exact methodology or the specific valuation inputs used in the investor’s stress test, as well as the exact “price” level referenced in the headline. The report also does not provide a full set of figures in the information available here, so readers cannot verify how the investor weighted growth versus profitability scenarios or how sensitive the result was to changing assumptions.

Why It Matters

  • A “cheaper than expected” stress-test conclusion can influence sentiment among investors focused on valuation rather than only on growth narratives.
  • The investor’s stated requirement for a specific lower entry price indicates that valuation concerns or uncertainty still exist, even if the risk/reward looks better than before.
  • If the stock’s market pricing stays volatile, investors may continue to anchor trading interest around valuation thresholds like the one referenced in the report.
  • The lack of disclosed inputs in the available information means the market may treat the claim as directional until more detail is provided.

Sources

Key Facts

  • A 247wallst report dated August 28, 2026 says a value investor ran Palantir through a valuation “stress test” and found it cheaper than expected.
  • The same report says the investor would not buy Palantir until a specific price level is reached.
  • The article includes a characterization that the investor still could not explain certain aspects of the situation fully, even after the stress-test conclusion.
  • Palantir is publicly traded on the Nasdaq under the ticker PLTR.

Technology Related